Rani Therapeutics Hldgs Stock (NASDAQ: RANI)

Rani Therapeutics Hldgs

RANI THERAPEUTICS HOLDINGS-A

Rani Therapeutics Holdings Inc is a clinical-stage biotherapeutics company advancing technologies to enable the development of orally administered biologics to provide patients, physicians, and healthcare systems with a convenient alternative to painful injections. The company has developed the RaniPill capsule, which is designed to deliver a wide variety of drug substances, including antibodies, proteins, peptides, and oligonucleotides. RaniPill is a proprietary and patented platform technology, intended to replace subcutaneous or IV injection of biologics with oral dosing. The company is also engaged in developing RaniPill HC, which is intended to enable the delivery of drug payloads in liquid form with high bioavailability.

Movers_Stocks

News

Pre-Market Outlook

Markets

Movers

Trading Ideas

APPS

AVGR

BBAI

COHR

DGLY

FORM

MBRX

MTRX

PTIX

RANI

RXRX

SBET

Market Index Target Term Securities Linked To The Dow Jones Industrial Average

SLXN

SWKS

Why Coherent Shares Are Trading Higher By Over 15%; Here Are 20 Stocks Moving Premarket

5 Stocks To Watch Heading Into Thursday

Analyst Color

Earnings

Equities

Futures

Economics

Analyst Ratings

AMZN

FTNT

NVDA

RBLX

SANG

U.S. stock futures rose on Thursday following Wednesday&#39;s advances as investors digest tariff pauses amid earnings reports.

US Stocks Likely To Open Higher Ahead Of Amazon&#39;s Earnings: &#39;Buy The Dip&#39; Mentality Remains Prevalent, Says Analyst

chart-1905225

Rani Therapeutics shares are trading lower by 23% Tuesday afternoon. The company announced a $10 million direct offering of 3 million shares at $3 per share.

Why Rani Therapeutics Shares Are Down 23% Today

Rani Therapeutics Holdings, Inc. - Class A Common Stock

Rani Therapeutics Holdings Inc

Health Care

Press Releases

Rani Therapeutics Announces New Preclinical Pharmacokinetic Data Supporting Transenteric Delivery of GLP-1 Incretin Triagonist

Peraso Inc. (NASDAQ: PRSO): Revolutionizing Military Combat with Steerable Beam Technology see more stocks inside…

Rani Therapeutics to Participate in Upcoming Investor Conferences

Rani Therapeutics Reports Third Quarter 2024 Financial Results; Provides Corporate Update

General

Rani Therapeutics Announces Preclinical Data Demonstrating Successful Oral Delivery of Semaglutide via RaniPill® HC

Rani Therapeutics to Report Fourth Quarter and Full Year 2024 Financial Results

Rani Therapeutics Announces Preclinical Data Demonstrating Bioequivalence of RT-114, a GLP-1/GLP-2 Dual Agonist (PG-102) Delivered Orally via the RaniPill® Capsule, to Subcutaneously Administered PG-102

Rani Therapeutics Reports Fourth Quarter and Full Year 2024 Financial Results; Provides Corporate Update

Rani Therapeutics Reports First Quarter 2025 Financial Results; Provides Corporate Update

Rani Therapeutics Announces Research Agreement with Chugai

BNZI

BREA

DRUG

ILLR

NIVF

NIXX

PRSO

STAF

TVGN

VMAR

VSME

XPON

Aspire Biopharma Holdings, Inc. - Common Stock

Aspire Biopharma Hldgs

Athira Pharma

Aytu BioPharma

CalciMedica

Cognition Therapeutics, Inc. - Common Stock

Cognition Therapeutics

Cingulate

Cocrystal Pharma

Citius Pharmaceuticals, Inc. - Common Stock

Citius Pharmaceuticals

Cadrenal Therapeutics, Inc. - Common Stock

Cadrenal Therapeutics

Dare Bioscience

Durect

Eyenovia

Gelteq

Hoth Therapeutics

Impact BioMedical

IGC Pharma

Kiora Pharmaceuticals, Inc. - Common Stock

Kiora Pharmaceuticals

Lexaria Bioscience

Lipocine

Lyra Therapeutics

MIRA Pharmaceuticals, Inc. - Common Stock

Mira Pharmaceuticals

ProPhase Labs

Relmada Therapeutics, Inc. - Common Stock

Relmada Therapeutics

TherapeuticsMD

VYNE Therapeutics

Oppenheimer

HC Wainwright & Co.

Canaccord Genuity

Maxim Group

Comments

Rani Therapeutics Hldgs

Connect With Us

About Benzinga

Market Resources

Trading Tools & Education

Ring the Bell